RVPH Share Price Performance
US$0.74
-18.33 (-96.11%)
98.9% undervalued intrinsic discount
US$70.00
Fair Value
Price US$0.74
iswrit US$70.00
Fair ValueUS$70.00
Share Pricen/a
Reviva Pharmaceuticals Holdings, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 21 Fair Values set on narratives written by author
RVPH Community Narratives
IS
Fair Value US$70 98.9% undervalued intrinsic discount
RVPH is poised to have a significant upper hand in the race to combat the rise in the niche mental health market.
2users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
RVPH is poised to have a significant upper hand in the race to combat the rise in the niche mental health market.
With the possibility of being the sole provider to combat skitsophrenia; once they complete phase three they will dominate their market. The drug brilaroxazine that they are working on has proved significant results but the FDA has made its harder for them to release it.Read more
68
users have viewed this narrative2users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Trending Discussion
Recently Updated Narratives
IS
RVPH is poised to have a significant upper hand in the race to combat the rise in the niche mental health market.
Fair Value: US$70 98.9% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Reviva Pharmaceuticals Holdings, Inc. Key Details
About RVPH
- Founded
- 2018
- Employees
- 14
- CEO
- WebsiteView website
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company’s lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer’s disease, and Parkinson’s disease psychosis; in clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
